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ABSTRACT OF THE THESIS 
 
The Value of a Genetics Evaluation for Patients with Suspected Ehlers-Danlos Syndrome or 
Other Possible Connective Tissue Disorder 
 
By 
 
Jacqueline Marie Ihinger 
 
Master of Science in Genetic Counseling 
 
 University of California, Irvine, 2019 
 
Professor Moyra Smith, MD, PhD, DACMG, Chair 
 
 
 
      Ehlers-Danlos syndrome (EDS) is a group of inherited connective tissue disorders (CTDs) 
characterized by hyperflexibility, skin hyperextensibility, and tissue fragility. As recently as 
2017, the International EDS Consortium published a new classification system with diagnostic 
criteria for thirteen different subtypes of EDS [Malfait et al., 2017]. The genetic etiology is 
known for all subtypes except hypermobile EDS (hEDS) which relies on clinical diagnostic 
criteria for diagnosis. Many patients are referred to the Genetics specialty for evaluation for EDS 
or other possible CTD. This study consisted of a retrospective chart review of referrals and 
Genetics consultation notes at one adult Genetics clinic to determine what types of providers are 
referring patients to the Genetics specialty, what types of evaluations (either imaging or 
evaluations by other specialties) patients are undergoing prior to seeing Genetics to further 
clarify if they may have a possible CTD, and what recommendations Genetics is making for 
these patients following evaluation. This study also compared patients who were self-referred 
and those who were referred by a provider and found there was no difference in the number of 
evaluations done prior to seeing Genetics nor the recommendations made after seeing Genetics. 
This study demonstrated that there is value in a Genetics evaluation for EDS or other CTDs 
 ix 
because patients are discussing more clinical features with Genetics providers, geneticists 
provide a comprehensive exam across all systems of the body, and genetic counselors are 
uniquely qualified to provide supportive counseling, education,  and resources this patient 
population needs.  
 
 
 
INTRODUCTION 
I. Connective tissue disorders 
Connective tissue provides the structural support for our body and organs. Connective tissue 
is composed of collagen and elastin. There have been 28 types of collagen described and 46 
genes encoding collagen proteins have been identified [Ricard-Blum, 2011, HGNC, 2018]. 
Mutations, or pathogenic variants, in many of these genes have been well described to cause a 
variety of connective tissue disorders (CTDs). There are more than 200 CTDs and many have 
overlapping features. Some well described CTDs include Ehlers-Danlos syndrome, Marfan 
syndrome, Loeys-Dietz syndrome, and Osteogenesis Imperfecta among many others. Pathogenic 
variants in the collagen genes (COL) as well as several other genes that contribute to the function 
of connective tissue can cause CTDs. While  many hereditary CTDs have been well described, 
there still remain some CTDs for which the genetic etiology has not yet been found or an 
individual may meet diagnostic criteria for a well-known CTD, but no gene mutation can be 
identified using the current molecular technology. 
 
II. History of Ehlers-Danlos syndrome classifications 
Ehlers-Danlos syndrome (EDS) is a group of CTDs with a wide range of phenotypes and 
disease classification that has varied over time. The 1986 International Nosology of Heritable 
Disorders of Connective Tissue Workshop held in Berlin classified eleven different types of EDS 
and named the subtypes with roman numerals (EDS I-XI) [Beighton et al., 1988]. With 
increasing clinical experience and biochemical and molecular studies, the Villefranche nosology 
proposed six types of EDS in 1997. These six subtypes were each given descriptive names to 
replace the roman numeral classification system and were each given major and minor diagnostic 
criteria [Beighton et al., 1998]. As recently as January 2017, the International EDS Consortium 
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proposed a new classification system of thirteen different subtypes of EDS [Malfait et al., 2017]. 
Each of the thirteen subtypes was given a descriptive name in line with the 1998 Villefranche 
classification (Appendix A). Currently, the molecular etiology is known for twelve of the 
thirteen subtypes of EDS and each subtype has been given both major and minor diagnostic 
criteria. While there are thirteen different subtypes, the most common subtypes of EDS are 
Classical EDS (cEDS), Vascular EDS (vEDS), and Hypermobile EDS (hEDS). Individuals are 
often referred to the Genetics specialty for suspicion of EDS or other possible CTD. Geneticists 
and genetic counselors provide a multisystemic assessment, give appropriate patient referrals and 
resources, and order genetic testing which can confirm a diagnosis of an EDS subtype with 
known molecular etiology. Genetic testing is unable to confirm a diagnosis of  the hEDS 
subtype, for which the genetic cause has not yet been identified [Malfait et al., 2017].        
 
III. Classical Ehlers-Danlos syndrome 
Classical EDS (cEDS) is an autosomal dominant subtype of EDS affecting approximately 1 
in 20,000 individuals [Byers, 2001]. Major diagnostic criteria for cEDS includes skin 
hyperextensibility and atrophic scarring and generalized joint hypermobility (GJH). Other minor 
features of cEDS are dislocation and/or subluxation due to increased join instability, velvety skin 
that can bruise easily, skin fragility, molluscoid pseudotumors, subcutaneous spheroids, hernia, 
and epicanthal folds (Appendix B). Muscle hypotonia and skeletal differences such as scoliosis, 
pectus deformities, elbow/genus/hallux valgus, and bone fragility may also be present.  Vascular 
findings such as mitral valve prolapse have been reported in individuals with cEDS but are much 
less common than in other subtypes of EDS. Mitral valve prolapse occurs in about 6% of cases 
of cEDS and aortic root dilation has been reported but rarely progresses to aortic dissection, 
which can be fatal when it does occur. Individuals with cEDS are at risk for surgical 
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complications due to skin extensibility and fragility. Women with cEDS are also at risk for 
premature rupture of fetal membranes during pregnancy [Bowen et al., 2017]. Over 90% of cases 
of cEDS are caused by pathogenic variants in the COL5A1 and COL5A2 genes that disrupt the 
function of type V collagen [Malfait et al., 2017]. A particular variant, c.934C>T (p.Arg312Cys), 
in the COL1A1 gene (a type I collagen encoding gene) has also been reported in unrelated 
individuals with cEDS. The majority of pathogenic variants in the  COL1A1 gene cause a 
different CTD called Osteogenesis Imperfecta [Nuytinck et al., 2000; Malfait et al., 2007] which 
can have some clinical overlap with cEDS. There is no cure for cEDS, but symptoms can be 
managed by avoiding trauma to the skin and joints, and treatment with anti-inflammatory drugs 
or other pain medications for joint pain. Surveillance includes routine echocardiograms to 
monitor for aortic root dilation and mitral valve prolapse, and monitoring pregnancies or 
surgeries carefully [Bowen et al., 2017]. 
 
IV. Vascular Ehlers-Danlos syndrome 
Vascular EDS (vEDS, previously EDS type IV) is a rarer, more severe autosomal dominant 
form of EDS affecting 1 in 150,000 people. Major diagnostic criteria for vEDS includes arterial 
rupture at a young age, spontaneous sigmoid colon perforation in the absence of a known 
diverticular disease or other bowel pathology, and uterine rupture during the third trimester in the 
absence of previous C-section and/or severe peripartum perineum tears. Additional minor 
characteristics include: bruising in the absence of trauma, thin, translucent skin, characteristic 
facial features, spontaneous pneumothorax, acrogeria (premature aging of skin), club foot, 
congenital hip dislocations, tendon or muscle rupture, gingival recession, early onset (under age 
30 and nulliparous) of varicose veins (Appendix C)[Malfait et al., 2017]. Unlike other forms of 
EDS, patients with this subtype of EDS do not have GJH or skin hyperextensibility [Pepin et al., 
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2000; Malfait et al., 2017]. As is indicated in the diagnostic criteria, individuals with vEDS are 
prone to ruptures of the arteries (thoracic or abdominal) or other organs such as the uterus or 
bowels and spontaneous pneumothorax. More than 80% of individuals with vEDS have a 
medical or surgical complication by age 40 [Pepin et al., 2000; Malfait et al., 2017]. Due to the 
risk of organ rupture, the average life expectancy of these patients is 48-51 years old [Pepin et 
al., 2000; Frank et al., 2019].  
Although there is no cure for vEDS, a molecularly confirmed diagnosis of vEDS can 
influence surveillance, surgical management, pregnancy management, and reproductive 
counseling. Vascular EDS is caused by mutations in the COL3A1 gene, a type III collagen 
encoding gene [Frank et al., 2015]. There are three rare COL1A1 variants (c.934C>T, 
p.Arg312Cys; c.1720C>T, p.Arg574Cys; c.3277C>T, p.Arg1093Cys) that have been reported to 
cause the same vascular fragility as seen in patients with COL3A1-associated vEDS [Malfait et 
al., 2017]. A molecularly confirmed diagnosis of vEDS has been shown to decrease surgical 
complications and mortality following emergent surgical intervention because different surgical 
measures may be undertaken when the patient has a known tissue fragility condition [Shalhub et 
al., 2014]. There are currently no cures or preventative measures for the vascular events seen in 
patients with vEDS. However, patients with vEDS should establish care with a care team, 
including a vascular surgeon, who are well versed in the risks associated with vEDS. These 
individuals are also encouraged to wear a medical alert bracelet and/or carry an emergency letter 
alerting other health care providers of their condition. Arterial screening can be performed, but 
there are no guidelines surrounding elective repair of unruptured aneurysms [Pepin et al., 2000]. 
Surgical intervention can be lifesaving in the event of arterial or organ rupture, but minimal 
surgical exploration is undertaken to prevent further tissue damage [Byers, 1999]. Pregnant 
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women with vEDS should be considered high risk and followed at a specialized center [Pepin et 
al., 2000]. 
 
V. Hypermobile Ehlers-Danlos syndrome 
The most common subtype of EDS is hypermobile EDS (hEDS, previously called EDS type 
III). It was previously thought that hEDS affects 1 in 5,000 individuals, but with recent 
reclassification of the diagnostic criteria for hEDS becoming more stringent, the prevalence of 
hEDS is unclear [Castori et al., 2010; Forghani, 2019]. Patients with hEDS typically present with 
joint hypermobility on the same spectrum as patients with benign joint hypermobility syndrome 
[Castori et al., 2010]. They may also present with recurrent dislocations, velvety skin, piezygotic 
papules, propensity to bruising, chronic joint pain, abdominal pain or gastrointestinal discomfort, 
and anxiety or depression [Castori et al., 2010]. Hypermobile EDS has several overlapping 
features with other types of EDS, but the features may vary in severity. For example, individuals 
with hEDS are described to have soft, velvety skin and they may have semi-transparent skin but 
these features are much more subtle than in individuals with vEDS [Tinkle et al., 2017]. 
Gastrointestinal complaints such as dysphagia, reflux disease with or without hiatal hernia, 
irritable-bowel disease-like symptoms, constipation, and diarrhea can occur in cEDS but are 
more common in hEDS [Bowen et al., 2017].  
In one study of individuals with hEDS, more than 99% of individuals with hEDS reported 
experiencing pain on a regular basis [Murray et al., 2013]. Both acute and chronic pain are 
reported by individuals with hEDS. Some possible etiologies of the pain these individuals 
experience are spasms of muscles, tendons, or other connective tissues, direct trauma due to joint 
instability, and osteoarthritis [Tinkle et al., 2017; Syx et al., 2017]. Pain is a reported symptom in 
other forms of EDS, but pain frequency and intensity is higher in hEDS than cEDS [Bowen et 
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al., 2017]. Pain contributes to impairment of daily functioning in individuals with hEDS but 
treatment is poorly defined and developed [Syx et al., 2017; Rombaut et al., 2011]. Pain 
management typically comprises of medications such as analgesics, topical agents such as 
lidocaine, cannabis where allowed by law, and opioids. Lifestyle changes such as avoiding high 
impact, high resistance activities and physical therapy focusing on strengthening and joint 
stability have also been recommended to improve pain symptoms [Rombaut et al., 2011; Tinkle 
et al., 2017]. Surgical intervention for joint stability has been performed as well, but the results 
of such surgeries are limited, and in a survey of patients’ relief of symptoms post-surgical 
intervention, only 33.9% of individuals reported a positive effect [Rombaut et al., 2011].  
Cardiovascular features are not a main feature of hEDS, but studies have found that children 
and young adults with hEDS can have mild aortic root dilation or mitral valve prolapse 
[McDonnell et al., 2006; Atzinger et al., 2011]. Longitudinal studies have found that aortic root 
dilation is unlikely to progress and does not usually require any treatment [Atzinger et al., 2011; 
Ritter et al., 2017]. While individuals with hEDS may be at an increased risk for mitral valve 
prolapse (6% compared to 1% in the general population), Atzinger et al. [2011] found only one  
of 252 individuals had moderate-to-severe mitral valve prolapse. Therefore, Atzinger et al. 
suggest that routine echocardiogram screening may be unnecessary for individuals with hEDS in 
the absence of cardiac symptoms or a striking family history [Atzinger et al., 2011].  
Studies have found associations with hEDS and mast cell activation disorders (MCADs), 
postural tachycardia syndrome (POTS), fatigue, anxiety, and depression. In recent years, there 
have been reports of MCAD and POTS in individuals with hEDS and joint hypermobility 
[Bonamichi-Santos et al., 2018]. It is well known that mast cells reside in connective tissues and 
play a role in tissue homeostasis and coordination of immune responses, but the exact 
mechanism of MCAD’s contribution to hEDS is still under investigation [Seneviratne et al., 
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2017a]. While there have been several studies showing an association of MCAD and POTS in 
individuals with hEDS, these case studies have involved small numbers of individuals and POTS 
and MCAD are not currently a part of the diagnostic criteria for hEDS [Wallman et al., 2014; 
Bonamichi-Santos et al., 2018; Seneviratne et al., 2017a].  
Fatigue, anxiety, and depression are commonly reported among individuals with hEDS. In a 
survey of 466 individuals with a diagnosis of hEDS made in a clinic or hospital, Murray et al. 
[2013] found that 82% of participants reported chronic fatigue, 73% reported having anxiety, and 
69% reported experiencing depression. Fatigue has been described as both mental and physical 
in patients with hEDS and may contribute to decreased muscle control, increased risk for injury, 
sleep disturbances, anxiety and depression [Tinkle et al., 2017]. The fatigue, chronic pain, and 
lack of effective treatment likely contribute to the psychological distress and dysfunction that 
many individuals with hEDS report [Syx et al., 2017; Sinibaldi et al., 2015]. These factors can 
contribute to resentment, distrust, and hostility towards peers, family, and health care providers 
[Tinkle et al., 2017] and likely contribute to the decrease in quality of life that has been reported 
in individuals with hEDS [Murray et al., 2013; Tinkle et al., 2017].      
The genetic etiology of hEDS has not yet been identified. However, based on family studies 
hEDS is described as an “autosomal dominant disorder ‘influenced by sex,’ with a predominance 
of symptoms in females” [Tinkle et al., 2017]. There have been case reports of hEDS due to 
variants in the tenascin X (TNXB) gene. Zweers et al. found haploinsufficiency of TNXB in 9 out 
of 14 females who had joint hypermobility, skin hyperextensibility and easy bruising [Zweers et 
al., 2003]. A novel missense variant, c.12172C>G (p.C4058W), in the TNXB gene has also been 
described in seven families that have a phenotype consistent with hEDS [Morissette et al., 2015]. 
In order to try to better understand the molecular background of hEDS, Chiarelli et al. performed 
immunofluorescence analysis and gene expression profiling of cultured fibroblasts in five 
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individuals with hEDS/joint hypermobility syndrome. Their findings suggest that several 
different signaling cascade pathways are required for the maintenance of the extracellular matrix 
(structure of connective tissue) architecture and homeostasis in patients with hEDS/joint 
hypermobility, and therefore, several different signaling cascades are involved in the 
multisystemic phenotype of these patients [Chiarelli et al., 2016].  
Despite these case studies, it remains that the cause of the vast majority of hEDS cases is 
unknown and diagnosis relies on meeting clinic criteria, most recently defined in the 2017 
International Classification of the Ehlers-Danlos Syndromes [Malfait et al., 2017]. Clinical 
diagnostic criteria incorporates Beighton score to assess generalized joint hypermobility. The 
Beighton score measures hypermobility on a 9-point scale: 1 point for each pinky finger (right 
and left) that extends back beyond 90 degrees when the palm and forearm are flat on a surface, 1 
point for each thumb (right and left) that can passively be moved to touch the underside of the 
forearm when the arm is extended, 1 point for each elbow (right and left) that extends beyond 10 
degrees when arms are outstretched to the sides and the palms are face up, 1 point for each knee 
(right and left) that extends beyond 10 degrees backward when the knees are locked, and 1 point 
for bending over to touch both palms flat on the floor from a standing position with straight legs. 
The diagnostic criteria also incorporates other clinical features previously described, chronic 
widespread pain, a positive family history, as well as exclusion of other connective tissue 
disorders [Malfait et al., 2017]. The Ehlers Danlos Society has created a diagnostic checklist for 
doctors across all disciplines to use to diagnose hEDS (Appendix D). 
 
VI. Other subtypes of Ehlers-Danlos syndrome 
There are three subtypes of EDS with autosomal recessive inheritance (Classic-like EDS, 
Cardiac-valvular EDS, and Kyphoscoliotic EDS) that share some features with the more 
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common subtypes of EDS previously discussed. Classical-like EDS (clEDS) is caused by 
biallelic mutations or deletions of the TNXB gene. Individuals with clEDS may exhibit 
generalized joint hypermobility, skin hyperextensibility, velvety skin, easy bruising skin, mild 
proximal and distal muscle weakness, atrophy of muscles in the hands and feet, acrogeric hands, 
mallet fingers, clinodactyly, brachydactyly, vaginal/uterus/rectal prolapse, or foot deformities 
such as pes planus, hallux valgus, or piezygotic papules [Malfait et al., 2017].  
Cardiac-valvular (cvEDS) is caused by biallelic mutations in the COL1A2 gene leading to 
defects in type I collagen. Individuals with cvEDS have severe progressive cardiac-valvular 
problems, most often involving the aortic or mitral valves. Individuals with cvEDS may also 
have skin hyperextensibility, atrophic scarring, thin skin, easy bruising, joint hypermobility, 
inguinal hernias, pectus deformity, joint dislocations, and foot deformities such as pes planus or 
hallux valgus [Malfait et al., 2017].  
Kyphoscoliotic EDS (kEDS) is caused by biallelic mutations in the PLOD1 and FKBP14 
genes. Major diagnostic criteria for kEDS includes congenital muscle hypotonia, congenital or 
early onset kyphoscoliosis, and joint hypermobility. Individuals with kEDS due to mutations in 
the FKBP14 gene can have congenital hearing loss, follicular hyperkeratosis, muscle atrophy, 
and bladder diverticula. Individuals with kEDS more commonly have PLOD1 mutations and 
they often have skin fragility, scleral and ocular fragility or rupture, microcornea, and facial 
dysmorphism. These individuals also have an increased deoxypyridinoline to pyridinoline 
(Dypr/Pyr) ratio on urinalysis and therefore, laboratory confirmation of kEDS should start with 
Dypr/Pyr ratio urinalysis followed by molecular confirmation [Malfait et al., 2017].  
There are several other subtypes of EDS, many of which have overlapping features with the 
subtypes of EDS previously described such as joint hypermobility and skin and tissue fragility. 
Other types of EDS include: Arthrochalasia EDS, Dermatosparaxis EDS, Brittle Cornea 
 10 
syndrome, Spondylodysplastic EDS, Musculocontractural EDS, Myopathic EDS, and 
Periodontal EDS. Some of these more rare types of EDS have distinguishable features, for 
example there are unique skin findings and facial features associated with Dermatosparaxis EDS 
and early onset periodontitis and lack of attached gingiva associated with Periodontal EDS. 
[Malfait et al., 2017]. For the sake of this research, these other types of EDS will not be 
discussed in further detail, but it is important to note that all of these other forms of EDS also 
have a known molecular etiology such that identification of a pathogenic variant can confirm a 
diagnosis [Malfait et al., 2017]. 
 
VII. Hypermobility spectrum disorders 
Joint hypermobility is defined as the capability to move a joint beyond normal limits. 
Generalized joint hypermobility (GJH) is typically assessed by using the Beighton scoring 
system; individuals having a Beighton score of 4 or more out of 9 are said to have GJH 
[Beighton et al., 1988]. However, the scoring is somewhat subjective because it is influenced by 
the examiner [Castori et al., 2017]. GJH is a descriptor, not a diagnosis, and recently efforts have 
been made to classify individuals with joint hypermobility that lack other musculoskeletal 
features on a spectrum of Hypermobility Spectrum Disorders (HSDs). Castori et al. [2017] 
classified seven different categories of joint hypermobility based on which joints are 
hypermobile, Beighton score, and musculoskeletal features (Appendix E). The aim of classifying 
HSDs is to distinguish those individuals with joint hypermobility lacking other features from 
individuals who have hEDS or other CTDs [Castori et al., 2017]. It can be difficult to distinguish 
other CTDs, especially hEDS, because joint hypermobility is the main feature of many genetic 
disorders and joint hypermobility can also run in families as an isolated trait. Individuals may be 
found to have GJH based on Beighton score and a positive family history of joint hypermobility, 
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but lack the musculoskeletal criteria outlined in the new hEDS diagnostic criteria [Castori et al., 
2017; Malfait et al., 2017]. 
 
VIII. Other connective tissue disorders with overlapping features of Ehlers-Danlos syndrome 
Joint laxity is a common feature of many CTDs, skeletal dysplasias, and even mitochondrial 
and neuromuscular conditions [Castori et al., 2017]. There are several CTDs such as Marfan 
syndrome, Loeys-Dietz syndrome, and arterial tortuosity syndrome that have some overlapping 
features of EDS.  
Marfan syndrome is an autosomal dominant condition caused by heterozygous pathogenic 
variants in the FBN1 gene. The main features involve the cardiovascular, skeletal, and ocular 
systems. Individuals with Marfan syndrome can have mitral valve prolapse and aortic root 
dilation, similar to a subset of the hEDS and cEDS populations [Colombi et al., 2015]. However, 
individuals with hEDS do not show progression of aortic dilation in adulthood,  unlike 
individuals with Marfan syndrome [Colombi et al., 2015; Atzinger et al., 2011]. Other features of 
Marfan that can overlap with EDS are the Marfanoid body habitus, pectus deformity and 
arachnodactyly, but a distinguishing feature of Marfan syndrome is ectopia lentis, which affects 
approximately 60% of individuals with Marfan syndrome [Colombi et al., 2015; Pyeritz, 2013].   
Loeys-Dietz syndrome (LDS) is another autosomal dominant CTD that shares features such 
as risk for thoracic and abdominal arterial aneurysms or dissections with Marfan syndrome and 
vEDS [MacCarrick et al., 2014]. Individuals with LDS can present with velvety, thin, translucent 
skin, easy bruising and atrophic scarring similar to that seen in individuals with vEDS and cEDS 
[Bowen et al., 2017; Malfait et al., 2017; MacCarrick et al., 2014]. Some characteristics that may 
distinguish Loeys-Dietz are palatal abnormalities, craniosynostosis, and bifid uvula. There are no 
diagnostic criteria for LDS, but diagnosis can be confirmed in individuals with suggestive 
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features by identification of a pathogenic variant in the TGFBR1, TGFBR2, SMAD3, or TGFB2 
genes [MacCarrick et al., 2014].  
Similar to vEDS, Marfan syndrome, and LDS, arterial tortuosity syndrome (ATS) is 
characterized by risk for vascular events such as aneurysm and dissections. ATS is characterized 
by severe arterial tortuosity of the aorta and other arteries [Callewaert et al., 2014]. Individuals 
with LDS can also experience generalized arterial tortuosity [MacCarrick et al., 2014]. Other 
findings in individuals with ATS are similar to vEDS and cEDS such as soft skin, pectus 
deformity, joint laxity, inguinal or abdominal hernias, and arachnodactyly [Malfait et al., 2017, 
Callewaert et al., 2014]. Diagnosis of ATS is established in individuals with arterial tortuosity 
and biallelic pathogenic variants in the SLC2A10 gene [Callewaert et al., 2014]. Marfan 
syndrome, LDS, and ATS are just a few of the CTDs that have overlapping features with some 
of the subtypes of EDS. These and many other CTDs have particular features that distinguish 
them from EDS, but individuals with a CTD do not have every feature of the condition, so it is 
important to be aware of other possible differential diagnoses.  
 
IX. Role of genetics specialty in evaluating patients and diagnosing connective tissue 
disorders 
The Genetics specialty receives many referrals for the various types of EDS and to evaluate 
patients for a possible CTD. Medical geneticists and genetic counselors can provide a 
comprehensive evaluation for possible CTDs by conducting a physical exam, taking a three 
generation family pedigree, and discussing appropriate genetic testing. Medical geneticists and 
genetic counselors can also provide referrals for follow-up imaging or exams when appropriate 
and can provide patients with support group information or other patient resources.  
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Family history is an important tool when assessing an individual’s risk for inherited 
conditions. A three generation pedigree is collected during each initial Genetics evaluation. A 
pedigree indicating which relatives have a history of features associated with CTDs can help 
distinguish who is at risk of inheriting a disorder, which may be especially important in cases of 
disorders with life-threatening risks. In cases of vEDS, patients are often not diagnosed until 
after an organ rupture event or even postmortem [Pepin et al., 2000] thus highlighting the 
importance of capturing history of an event like this when taking a pedigree. Pedigrees can also 
help determine which relatives may be at risk of inheriting the same condition and can indicate 
familial testing if a pathogenic variant is found. 
Diagnostic criteria are helpful when conducting a physical examination to evaluate for a 
particular disorder or group of disorders. Physicians from any specialty can use the Ghent 
nosology to aid in diagnosing Marfan syndrome [Loeys et al., 2010] and the new 2017 diagnostic 
criteria for the various subtypes of EDS as outlined by Malfait et al. [2017]. When appropriate, 
genetic testing can be ordered to confirm a suspected diagnosis, with the exception of hEDS for 
which the genetic cause has not get been identified. Different types of genetic testing include 
gene panel tests that sequence multiple genes associated with different CTDs, familial variant 
testing when a pathogenic variant has been identified in a family member, single gene 
sequencing, and whole exome sequencing. While there are many benefits to genetic testing such 
as confirmation of a suspected diagnosis (which can allow for appropriate disease management) 
when a pathogenic or likely pathogenic variant is found, there are still costs and risks associated 
with genetic testing. One risk, and frustration, with genetic testing is when a patient’s testing 
identifies a variant of uncertain significance (VUS). A VUS is a variant for which there is not 
enough data to classify it as pathogenic, likely pathogenic, likely benign, or benign. Medical 
management and surgical decisions should not be made on the basis of an identified VUS, and 
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familial and prenatal testing are not offered for VUSs [Richards et al., 2015]. There is a risk that 
patients and providers may interpret a VUS as a “positive” result or pathogenic possibly resulting 
in inappropriate surgical management or possibly unnecessary screening. A VUS is an 
uninformative result that can cause frustration and anxiety for both provider and patient. 
Geneticists and genetic counselors can offer appropriate counseling and education to try to 
alleviate some of this anxiety. 
While there is great value in a Genetics evaluation for a possible CTD, it has been noted by 
the Genetics group at the University of California, Irvine Medical Center (UCIMC) that some 
Genetics groups are no longer seeing patients for this indication. Anecdotally, there has been an 
increasing number of referrals to the UCIMC for patients to be evaluated for EDS. Whether this 
is due to an increasing awareness of the condition, due to other Genetics groups not accepting 
referrals for CTDs, or due to other causes is unknown. Genetic counselors have written 
discussion board postings about how to triage an increasing number of referrals for EDS in 
Genetics clinics and where to find EDS specialists across the United States on the National 
Society of Genetic Counselors (NSGC) webpage, further supporting that more patients are being 
referred to Genetics clinics for this indication.  
 
X. Gaps in current knowledge and research 
As described, past studies have examined the clinical features of each subtype of EDS in 
detail and found some overlapping features of hEDS with other subtypes [Castori et al., 2010; 
Bowen et al., 2017; Frank et al., 2015]. Further research needs to be done to examine some of the 
unique associations specific to  hEDS such as MCAD [Seneviratne et al., 2017b] and POTS 
[Wallman et al., 2014]. There have not been studies that examine reported phenotypes of EDS 
patients over time as diagnostic criteria has changed or since the new criteria for hEDS was 
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published in March 2017 by the International EDS Consortium [Malfait et al., 2017]. One study 
surveyed individuals with hEDS about their lived experience with the syndrome. Although it was 
not the specific aim of this study, researchers asked what type of physician gave patients their 
diagnosis and what type of provider is managing their clinical care [Murray et al., 2013]. There 
remains to be research specific to diagnosing and treating these patients within the Genetics 
specialty. As previously mentioned, patients are referred to the Genetics specialty for an 
evaluation of EDS, yet there is little research specific to which types of providers are referring 
patients to the Genetics specialty and what types of other evaluations patients are undergoing, if 
any, prior to being referred to Genetics. With some Genetics groups not accepting referrals for 
CTDs it is important to understand the utility of a Genetics evaluation for these indications and 
try to create a strategy for an effective and efficient Genetics evaluation for EDS and CTDs.  
 
XI. Purpose and aims of this study 
This study is a retrospective chart review of referrals and clinical documentation of 
patients referred to the Genetics specialty at UCIMC. One aim of this study is to determine 
what types of providers are referring patients to the Genetics specialty for an evaluation of 
EDS or other possible CTD and what types of evaluations (either imaging or evaluations by 
other specialties) these patients undergo prior to seeing Genetics to further clarify if they may 
have a possible CTD. Given the update of diagnostic criteria for EDS published in 2017 and 
increasing awareness of EDS, it is hypothesized that more patients were referred to the 
Genetics specialty from a wider range of specialists and that there were increasing numbers of 
referrals from primary care physicians in the period since the guidelines were published. A 
second aim of this study is to determine if there is a correlation between types of referrals 
(self-referred vs. referred from another specialty) and the recommendations made after the 
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patient is seen by the geneticist. It is hypothesized that if the patient is self-referred to the 
Genetics clinic, then there will be more recommendations made by the geneticist following 
examination and the patient will require a second visit to the Genetics clinic. By exploring 
referrals specific to the Genetics specialty, this study helps us to better understand why 
patients are referred to Genetics and what the Genetics specialty can do for these patients, 
particularly patients with hEDS for which a genetic cause has not yet been identified.   
 
METHODS 
I. IRB Approval 
This study was approved by the University of California, Irvine (UCI) Institutional 
Review Board (IRB) under study HS# 2019-4925. 
 
II. Retrospective Chart Review 
Charts of patients at UCI Medical Center (UCIMC) who were referred to the Genetics 
specialty for an evaluation of EDS or to rule out a possible CTD were reviewed by the lead 
author. Charts from 2014 [when UCIMC began using an electronic medical record (EMR) 
system, Quest (2014-2017) and Epic (2017-2019)] through March 2019 were reviewed. Patients 
were identified by the referral indication entered into the secure electronic database of Genetics 
patients (FileMaker Pro). Patients were assigned a non-identifying patient number which 
corresponds to their medical record number in a secure coded key sheet. The coded key was kept 
on a secure UCIMC server.  
A total of 151 patients were identified as referred to and attempted to be scheduled in the 
Adult Genetics Specialty Clinic at UCIMC for an evaluation of possible EDS or to rule out a 
possible CTD from January 2014 to March 2019. The patient referrals, available imaging, and 
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medical documentation were reviewed. A data collection sheet was generated and used for 
subsequent analysis. No Protected Health Information (PHI) was collected and documented on 
the data collection sheet.  
A separate count of the total number of referrals, including those not yet attempted to be 
scheduled due to limited clinic availability or requests for more clinical information as part of the 
triage process, was completed by reviewing the referral indications listed in the UCIMC STARS 
referral tracking system (January 2014- October 2017) and the EPIC scheduling work queue for 
Genetics (November 2017-May 2019). If a patient had not been contacted in attempt to be 
scheduled, they were excluded from the chart review, but were counted as part of the larger 
referred group. 
Patient demographics such as age, sex, insurance type (PPO, HMO, 
Medicaid/Medicare/Tricare), year referred to Genetics, and year seen by Genetics were collected. 
The following information was collected from patient referrals to the Genetics specialty: 
specialty of referring provider, whether or not the patient was self-referred, clinical features 
listed on referral, whether or not family history was mentioned on referral, Beighton score if 
available, if genetic testing was mentioned or requested, previous genetic testing results if 
applicable, imaging studies, biochemical testing, and if the patient had seen Cardiology, 
Ophthalmology, Rheumatology, Orthopedics, or Immunology/Allergy specialists. Patients were 
categorized into two categories: self-referred and provider-referred. If a patient was had no 
referring provider listed (or listed as self) or if the referral mentioned the patient was requesting 
the referral to Genetics, they were categorized as “self-referred.”  
The following information was collected from the medical documentation from the medical 
geneticist and genetic counselor at UCIMC: Beighton score, whether or not the patient meets the 
2017 hEDS criteria 2 (see Appendix D), clinical features noted on physical exam, if a diagnosis 
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of hEDS was given, if other differential diagnoses were noted and if so, which other conditions 
were included, and if recurrence risk was discussed. To gain an assessment of family history of 
possible connective tissue disorders, the number of maternal and paternal first and second degree 
relatives reported to have a diagnosis of EDS or “features of EDS or other possible connective 
tissue disorders” were extracted from the Family History section of the Genetics documentation. 
The “features of EDS or other possible connective tissue disorders” included a reported history 
of: hypermobility, hyperflexibility, joint pain, dislocations, subluxations, smooth/velvety skin, 
easy bruising, hyperextensible skin, atrophic/abnormal scarring, GI disturbances, POTS 
manifestations, mast cell activation disorder, myopia, detached retina, ruptured aorta, dilated 
aorta, mitral valve prolapse, organ rupture, and sudden death under age 50 (not accidental).  
 The recommendations made by the medical geneticist and genetic counselor following 
the evaluation were also collected. Information was collected on whether or not imaging studies, 
biochemical testing, referrals to other specialists, records requests, and a return visit was 
recommended. Finally, information was collected on what type of genetic testing was offered to 
the patient: single gene testing, larger gene panel, SNP microarray, whole exome sequencing, or 
none. Genetic testing results were recorded if available.  
 Eighteen patient charts (12%) randomly selected from across the study period (January 
2014-March 2019) were re-analyzed for all variables. Initially analyzed charts were compared to 
the re-analyzed charts to determine a data collection error rate of 3.0%. 
 
III. Data Analysis 
Data were analyzed using the IBM Statistical Package for the Social Sciences (SPSS) 
Statistics version 26 (IBM SPSS Statistics for Macintosh, Armonk, NY, USA, IBM Corp). 
Patient demographics, referral features, Genetics exam features, and Genetics recommendations 
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were summarized using means and standard deviations for continuous variables and counts and 
percentages for categorical variables. Paired t-test and chi-square values were calculated using 
SPSS. P-values <0.05 were considered statistically significant.  
 
RESULTS 
I. Referral information 
A retrospective chart review was conducted to determine how many patients were 
referred to the Genetics specialty for an evaluation of EDS or other possible CTD, what types of 
providers are referring these patients, what types of evaluations these patients are undergoing 
prior to seeing Genetics, the outcome of the Genetics evaluation, and what recommendations 
were made by the Genetics team. The number of referrals were counted for each year from 
January 2014- May 2019 for a total of 255 referrals to Genetics for an indication of EDS or other 
possible CTD (Table 1a). A total of 93 referrals were made to UCIMC Genetics prior to the 
publication of the new hEDS diagnostic criteria by Malfait et al. [2017] (January 2014-December 
2016) and 162 referrals were made after the publication of new hEDS diagnostic criteria 
(January 2017-May 10, 2019) (p<0.001) (Table 1b). Moreover, the number of referrals counted 
for 2017 and 2018 are known to be an underestimate due to technical issues regarding referral 
tracking in the EMR after November 2017. Referrals were counted through May 10, 2019 and 
therefore do not represent a full year for 2019. The referrals that were missed in the counts for 
these years are representative of the total number of referrals that were counted in terms of 
referral indication and phenotype and are not expected to represent patients that may have had a 
higher or lower burden of EDS.  
If a patient had not been contacted in attempt to be scheduled, they were excluded from 
the chart review. A total of 151 patients were identified as referred to and attempted to be 
scheduled in the Adult Genetics Specialty Clinic at UCIMC for an evaluation of possible EDS or 
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to rule out a possible CTD from January 2014 to March 2019.  These 151 patient referrals were 
reviewed. Of those 151 patients, 128 completed a visit at UCIMC and their Genetics consultation 
note was reviewed (Table 1). Twenty-three patients were attempted to be scheduled so their 
referral was analyzed but they did not complete a Genetics consultation so there was no Genetics 
note to review.  
 
Table 1a. Number of patients by year   
Year 
Total Referrals No. Patient Referrals Reviewed 
No. Patient 
Genetics Notes 
Reviewed 
(N=255) (N=151) N=128) 
2014 23 26a 21 
2015 38 38 28 
2016 32 30 24 
2017 82b 26 27 
2018 45c 30 22 
2019 35d 1e 6e 
aThree referrals from 2013 were included in the analysis because the 
patient was seen by Genetics in 2014. The remainder of patients seen 
in 2014 were referred in 2014. 
bMonths of November and December not accounted for due to 
transition to new EMR 
cNot all referrals accounted for due to transition to new EMR 
dJanuary 1, 2019- May 10, 2019 
eJanuary 1, 2019- March 31, 2019 
 
Table 1b. Number of referrals prior to and after the publication of new hEDS diagnostic 
criteria by Malfait et al. [2017] 
No. referrals prior to new hEDS criteria publication  93 
No. referrals after new hEDS criteria publication 162 
     p<0.001 
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The demographic characteristics of the patients were analyzed (Table 2). Age of patients 
ranged from 18-68 years with a mean age of 36.8 years. The majority (76.2%) of patients were 
female and the majority of patients had private insurance (73.5%). 
 
Table 2. Demographic information 
Characteristic (N=151) 
N (%) 
Age (Range) 18-68 
Age (Mean/SD) 36.8/13.0 
Age  
18-27 42 (27.8) 
28-37 45 (29.8) 
38-47 28 (18.5) 
48-57 24 (15.9) 
58-67 11 (7.3) 
68-77 1 (0.7) 
Sex   
Female 115 (76.2) 
Male 36 (23.8) 
Insurance Type  
Private 111 (73.5) 
Government 32 (21.2) 
Dual Coverage 6 (4.0) 
Self-pay 2 (1.3) 
  
 
 Fifteen different types of providers referred patients to the genetics specialty for an 
evaluation of EDS or to rule out another possible CTD. Thirty-six percent of the referrals were 
from general practice physicians (primary care, internal medicine, and family medicine 
physicians), 31% were from Rheumatology, 9% were from Neurology, and 4% were from 
Cardiology (Figure 1). 
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 Of the 151 referrals analyzed, 33 had a Beighton score documented on the referral. The 
Beighton score on the referral was compared to the Beighton score calculated at the Genetics 
exam, and 19 patients were found to have different Beighton scores once they were seen in 
clinic. For 6 of those 19 patients, the Beighton score given by the geneticist changed whether or 
not they met the Beighton score criteria based on their age for a diagnosis of GJH. Four patients’ 
Beighton score decreased to no longer meeting the age specific cut-off for GJH (Figure 2). 
36%
31%
4%
9%
3%
3%
3%
2%
3%
7%General Practice
Rheumatology
Cardiology
Neurology
Genetics
Gastroenterology
No provider listed
Orthopedics
OB/GYN
Other (Endocrinology, Dermatology, Immunology/Allergy,
Hematology, Pulmonology, Hospitalist, Pain Management)
N=151
Figure 1. Referring providers by area of practice. Referrals were received from 15 
different types of providers. The most common referring provider was a general practice 
physician (primary care/family medicine/internal medicine) (36%) followed by 
rheumatologist (31%), neurologist (9%), and cardiologist (4%). Smaller percentages of 
referrals came from geneticists, gastroenterologists, orthopedists, 
obstetricians/gynecologists, endocrinologists, dermatologists, immunologist/allergists, 
hematologists, pulmonologists, hospitalists, and pain management specialists. 
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Beighton score on referral 
(33)
Beighton score on referral 
is same as Beighton score 
on Genetics exam
(6)
Beighton score on referral 
is different from Beighton 
score on Genetics exam 
(19)
Beighton score calculated 
at Genetics exam changed 
diagnosis of GJH
(6)
Beighton score increased to 
meet cutoff for diagnosis of GJH
(2)
Beighton score decreased to no 
longer meet cutoff for 
diagnosis of GJH
(4)
Beighton score calculated 
at Genetics exam did not 
change diagnosis of GJH 
(13)
Patients not see by 
Genetics 
(5)
Beighton score not 
calculated at Genetics 
exam 
(3)
Referring Providers: 
Rheumatology (16)   
Gen. Practice (14)  
Genetics (2)
Gastroenterology (1)
Figure 2. Differences in the Beighton score documented on referral and the Beighton 
score given on the Genetics exam. Thirty-three referrals had a Beighton score documented. 
The majority of these referrals came from rheumatologists (16) and a particular general 
practice physician in the community who sees many patients for concerns of EDS (14). 
Nineteen patients were found to have different Beighton scores once they were seen in clinic. 
For 6 of these 19 patients, the score given by the geneticist changed whether or not they met 
their age-specific criteria for a diagnosis of generalized joint hypermobility (GJH). 
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 Comparisons were made between self-referred and provider-referred patients to 
determine if self-referred patients were more or less likely to have EDS-related evaluations prior 
to seeing Genetics and to determine if more or fewer recommendations were made after the 
Genetics evaluation for self-referred patients. A total of 34 (22.5%) patients were considered 
self-referred (defined by having no referring provider listed or if the referral mentioned the 
patient was requesting the referral to Genetics). Medical charts and referrals were reviewed to 
determine if the patient had EDS-related imaging studies (i.e. echocardiogram, CT, MRI, DEXA 
scan) performed or if the patient had seen Cardiology, Ophthalmology, Rheumatology, 
Orthopedics, or Immunology/Allergy specialists prior to seeing Genetics. The number of patients 
who had performed each type of evaluation listed in Table 3 were then stratified by referral 
status (self vs provider) and compared using Chi square; no statically significant difference was 
found between the two groups for any of the evaluations examined (Table 3). 
 
Table 3. Evaluations performed prior to seeing Genetics  
Total Self-referred  Provider-referred   
N=151 N=34 N=117  
Evaluation N (%) N (%) N (%) p-value 
EDS-related imaging studies 115 (76.2) 22 (64.7) 93 (79.5) 0.097 
Seen by Cardiology 54 (35.8) 10 (29.4) 44 (37.6) 0.380 
Seen by Ophthalmology 27 (17.9) 3 (8.8) 24 (20.5) 0.117 
Seen by Rheumatology 69 (45.7) 16 (47.1) 53 (45.3) 0.856 
Seen by Orthopedics 24 (15.9) 7 (20.6) 17 (14.5) 0.395 
Seen by Immunology/Allergy 19 (12.6) 5 (14.7) 14 (12.0) 0.672 
 
Each clinical feature (i.e. physical features, medical diagnoses, and patient reported 
symptoms) listed on the patient’s referral and Genetics consultation note was counted and 
grouped into different phenotypic categories (see Appendix F for all of the individual features 
that were reported and grouped into each category). The percentage of patients with at least one 
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feature in the given categories documented on their referral and their Genetics note is displayed 
in Figure 3 (see Appendix G for a table of the number of patients with at least one reported 
feature in each of the categories). Some patients had multiple features in some categories. 
Musculoskeletal findings were the most common features noted on both referrals (85.4%) and 
Genetics notes (97.7%). All features were more frequently reported or noted on the Genetics 
exam with the exception of hearing loss and metabolic findings, but one of the patients who had 
a metabolic finding reported on their referral was not seen by Genetics. On average referrals 
listed 3.8 clinical features while Genetics notes listed 7.1 clinical features (p<0.001) (Table 4, 
Figure 4).  
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Figure 3. Clinical features listed on referrals and Genetics consultation notes. The 
percentage of patients with at least one clinical feature in the given phenotypic categories 
were compared between the referral (green) and the Genetics note (blue). Some patients had 
multiple features in some categories.  Percentage indicates the proportion of the total number 
of patients for each category (referrals N=151, Genetics notes N=128).  
N=151       N=128 
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Table 4. Average number of clinical features listed on referrals and Genetics 
consultation notes 
  Range Average 
Number of features listed on referral 0-13 3.8 
Number of features listed on Genetics consultation note 1-14 7.1 
  p<0.001 
 
 
 
 
 
Figure 4. Distribution of the number of clinical features listed on patient referrals 
and Genetics notes. The number of clinical features (i.e. physical features, medical 
diagnoses, and patient reported symptoms) listed on each patient referral (green) and 
Genetics note (blue) were counted and compared. The distribution of the number of 
features demonstrates that more features were listed on the Genetics notes than on the 
referrals. The individuals with “0” features had no physical features and only “family 
history of EDS” reported on the referral. 
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II. Patients who were given a diagnosis of hEDS  
Thirty-four (26.5%) patients were given a diagnosis of hEDS following their Genetics 
evaluation. These patients ranged in age from 19-60 with an average age of 37.4, and 91.2% of 
these patients were female (Table 5).  The clinical symptoms and physical features that were 
reported by these patients or were noted by the geneticist during their Genetics consultation were 
categorized by phenotype. Figure 5 shows the percentage of hEDS patients who reported or were 
found to have at least one feature in the different phenotypic categories noted on their Genetics 
consultation note. All of the patients who were given a diagnosis of hEDS had musculoskeletal 
findings, 8.8% had vascular system findings, 35.3% reported cardiac findings, 55.9% reported 
gastrointestinal findings, 8.8% reported genitourinary findings, 61.8% reported having or had 
skin findings on physical exam, 32.4% reported immunologic findings, 2.9% reported endocrine 
findings, 55.9% reported neurological findings, 8.8% had structural brain abnormalities, 32.4% 
reported behavioral findings, and 17.6% had dental findings on physical exam. On average 
patients who were given a diagnosis of hEDS had 8.5 clinical features noted in their Genetics 
consultation note, while patients who were not given a diagnosis of hEDS had an average of 6.6 
features noted (p=0.003) (Table 6, Figure 6). Of the 34 individuals who were given a diagnosis 
of hEDS, 25 (73.5%) were given referrals to other specialists including: Physical Therapy, Pain 
Management, Ophthalmology, Cardiology, Neurology, Rheumatology, Immunology/Allergy, 
Orthopedics, and a provider in the community that sees many patients with EDS and 8 (23.5%) 
had imaging studies ordered including echocardiogram, brain MRI, electrocardiogram, and 
DEXA scan. Eleven (32.4%) of these patients had a Beighton score given on their referral; these 
account for 1/3 of the total referrals that had a Beighton score prior to seeing Genetics.  
Twenty-two patients (64.7%) with hEDS had genetic testing recommended by Genetics. Of 
these 22 patients, 3 patients’ genetic testing identified variants of uncertain significance, 1 
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patient (patient #300) had positive genetic testing from whole exome sequencing (WES) that 
explained  some of his clinical features, but not his hEDS features (see description in Results 
section III), 7 patients had negative results, 3 patients’ testing was ordered but denied by 
insurance, and no record of genetic testing being ordered was found for the remaining 8 patients. 
Eight patients who were given a diagnosis of hEDS were discharged from the Genetics clinic 
following their initial consultation. Twenty-six patients were recommended to arrange a return 
visit to Genetics, most of whom were recommended to return to discuss genetic testing results. 
Seven patients with hEDS returned to clinic for at least one follow-up visit, which accounts for 
almost half (46.7%) of the total number patients who were seen for an evaluation of EDS or 
other possible CTD who returned for a follow-up visit. 
 
Table 5. Demographic information of 
individuals who were given a diagnosis of hEDS 
Characteristic (N=34) 
  N (%) 
Age (Range) 19-60 
Age (Mean/SD) 37.4/12.2 
Age  
18-27 8 (23.5) 
28-37 9 (26.5) 
38-47 8 (23.5) 
48-57 8 (23.5) 
58-67 1 (3.0) 
68-77 0 (0) 
Sex  
Female 31 (91.2) 
Male 3 (8.8) 
 
 29 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Mu
scu
los
ke
let
al F
ind
ing
s
Va
scu
lar
 Fin
din
gs
Ca
rdi
ac 
Fin
din
gs
Ga
str
oin
tes
tin
al F
ind
ing
s
Ge
nit
ou
rin
ary
 Fin
din
gs
Ski
n F
ind
ing
s
Im
mu
no
log
ic F
ind
ing
s
En
do
cri
ne
 Fin
din
gs
Ne
uro
log
ica
l Fi
nd
ing
s
Str
uct
ura
l B
rai
n A
bn
orm
alit
ies
Be
ha
vio
ral
 Fin
din
gs
De
nta
l Fi
nd
ing
s
N=34
Figure 5. Clinical features of individuals who were given a diagnosis of hEDS after 
Genetics evaluation. The percentage of patients with at least one clinical feature in the 
given phenotypic categories, as reported in the Genetics note. Percentage indicates the 
proportion of the number of individuals who were given a diagnosis of hEDS after Genetics 
evaluation (N=34).  
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III. Genetics recommendations and outcomes 
The recommendations of imaging studies, requests to review medical records, referrals to 
other specialists and return visits made following the Genetics consultation were counted and 
compared between the patients who were self-referred and provider-referred (Table 6). There 
was no statistically significant difference between the two groups. Patient charts were also 
examined for documentation of the recommendations made by Genetics being completed, in 
particular referrals to Cardiology and Ophthalmology because patients were referred to those 
specialists to be evaluated for other features of CTDs rather than management of their symptoms 
Figure 6. Distribution of the number of clinical features listed on the Genetics notes 
of patients who were given a diagnosis of hEDS and patients who were not given a 
diagnosis of hEDS. The number of clinical features listed on each patients Genetics note 
were counted and compared between individuals who were given a diagnosis of hEDS 
(blue) and individuals who were not given a diagnosis of hEDS (green). The distribution 
of the number of clinical features demonstrates that more features were listed in the 
Genetics notes of patients who were given a diagnosis of hEDS (N=34) than in the Genetics 
notes of patients who were not given a diagnosis of hEDS (N=94). 
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(Table 7). See Appendix H for a complete list of the referrals that were made to other specialists. 
When Cardiology and Ophthalmology records were available, the number of results that were 
abnormal/significant were counted (Table 7). Of the imaging that was recommended, an 
echocardiogram was the most common (recommended for 33 patients, 26%) (Table 8). Genetics 
received record of the echocardiogram being performed for 14 (42%) of the patients that were 
recommended to have an echocardiogram and of those 14 patients, 3 had abnormal 
echocardiograms (Figure 7). Two of the patients who had abnormal echocardiograms (patients 
#161 and #216) had a mildly dilated left atrium. Their echocardiograms were otherwise within 
normal limits. Patient #161 was given a diagnosis of hEDS and had features of hypermobility 
(Beighton score 8/9), joint pain, easy bruising, poor wound healing, POTS, 
dislocations/subluxations, migraines/headaches, scoliosis, and arthritis. Patient #216 was not 
given a diagnosis of hEDS. This patient reported being hyperflexible but received a Beighton 
score of 1/9, and her other clinical features were velvety skin, skin striae, reported easy bruising, 
gastrointestinal disturbances such as diarrhea, constipation, or IBS, myopia, and cecal volvulus. 
The third patient who had abnormal echocardiogram results (patient #91) is the same patient with 
an abnormal Cardiology exam (Table 7). Patient #91 was found to have aortic root and ascending 
aorta dilation and mitral valve prolapse. This patient had a family history of cEDS, but he tested 
negative for the familial variant in COL5A1 on a 21 gene Aortopathy panel. Whole exome 
sequencing was ordered but was denied by insurance. This patient’s other features consisted of 
hypermobility (Beighton score 5/9), joint pain, dislocations/subluxations, and an arm span: 
height ratio >1.05.  
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Table 6. Recommendations made after Genetics consultation  
 Total Self-referred Provider-referred  
 N=128 N=31 N=97  
Recommendation N (%) N (%) N (%) p-values 
Imaging studies 40 (31.3) 9 (29.0) 31 (32.0) 0.760 
Records requested to review 21 (16.4) 5 (16.1) 16 (16.5) 0.962 
Referrals to other specialists 63(49.2) 17 (54.8) 46 (47.4) 0.472 
Return visit recommended 103 (80.5) 25 (80.6) 78 (80.4) 0.977 
 
 
Table 7. Number of referrals placed to Cardiology and Ophthalmology following 
Genetics evaluation and the outcomes of those referrals 
  Record of Cardiology or 
Ophthalmology 
Seen 
Abnormal 
results  N=128 
Specialists N (%) N (%) N (%) 
Cardiology 21 (16.4) 7 (33.3) 1 (14.3) 
Ophthalmology 28 (21.9) 8 (28.6) 0 (0) 
 
 
Table 8. Number of referrals placed for imaging following Genetics evaluation 
and the outcomes of those referrals 
  Record of study 
received Abnormal Results  N=128 
Imaging Study N (%) N (%) N (%) 
Echocardiogram 33 (25.8) 14 (42.4) 3 (21.4) 
EKG 12 (9.4) 7 (58.3) 0 (0) 
Brain MRI 4 (3.1) 0 (0) N/A 
CT scan 2 (1.6) 1 (50.0) 1 (100.0) 
X-ray 1 (0.8) 0 (0) N/A 
DEXA scan 1 (0.8) 1 (100.0) 1 (100.0) 
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As previously mentioned, genetic testing recommendations were collected for all 
patients. Sixty percent of the total number of patients seen by Genetics had genetic testing 
recommended following their evaluation and 10% of patients had genetic testing recommended 
if Cardiology or Ophthalmology examinations were abnormal or following the retrieval of 
familial genetic testing records (Figure 8). A variety of different genetic tests were 
recommended. Fifty-two percent of genetic testing that was recommended were multi-gene 
panels, 18% were single-gene tests, 8% were SNP microarray, and 8% were whole exome 
sequencing (WES) (Figure 9). See Appendix I for a list of the single genes and multi-gene panels 
that were ordered. The majority of patients’ genetic testing results were negative (68%), but 3 
(6%) patients had positive results (Figure 10). As previously mentioned, one patient (#300) who 
was diagnosed with hEDS had positive WES. This patient was described to have hemiplegic 
58%
21%
79%
42%
No Report Results of echo available Abnormal Results Normal Results
Figure 7. Outcomes of echocardiograms that were recommended. Thirty-three 
patients were recommended to have an echocardiogram following their Genetics 
consultation. Genetics received record of the echocardiogram being completed from 14 
patients (42%). Of these 14 patients, 3 (21%) had abnormal echocardiogram results. 
Two patients (#161 and #216) had a mildly dilated left atrium and the third patient (#91) 
had aortic root and ascending aorta dilation and mitral valve prolapse. 
 
N=33 
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migraines in addition to his hEDS features of joint hypermobility (Beighton score 7/9), skin 
elasticity, high arched palate, gastrointestinal disturbances, and dislocations/subluxations. WES 
found a likely pathogenic variant in the CACNA1S gene. Variants in this gene can cause 
hypokalemic periodic paralysis, so this finding may explain the patient’s hemiplegic migraines 
but it does not explain his hEDS features. The second patient with positive genetic testing (#59) 
had a chromosome microarray ordered because he previously had an abnormal karyotype. This 
patient was referred for suspicion of Marfan syndrome and the Genetics exam noted features of 
arachnodactyly, myopia, spontaneous pneumothorax, kyphosis, and intellectual disability. This 
patient was found to carry a duplication of 9q34.11-q34.3 and a duplication of 15q11.2-q11.2. 
Duplication of 9q34 is a recognized duplication syndrome that can cause low birth weight, 
psychomotor delay, limited vocabulary acquisition, hyperactivity, joint contractures, long, thin 
limbs, and arachnodactyly. Marfan syndrome was a common initial diagnosis for affected 
individuals prior to cytogenetic and molecular studies [Allderdice et al., 1983]. Patient #59’s 
features fit the 9q34 duplication syndrome well. The final patient with positive genetic testing 
results (#36) had single gene COL3A1 sequencing ordered which found a pathogenic variant and 
he was given a diagnosis of vEDS. This patient was noted to have a family history of one first 
degree relative and two second degree relatives with a history of EDS features and on exam was 
reported to have an inguinal hernia, dislocations/subluxations, “EDS facial features,” carotid 
cavernous fistula, bowel obstruction, a history of clubfoot, and gingival recession. A CT 
angiogram was recommended at the initial Genetics visit and found nonocclusive thrombus in 
the left external iliac vein and focal dissection involving the distal left common iliac artery. 
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60%
10%
30%
Genetic Testing
Recommended at
Initial Visit
Genetic Testing
TBD
None
N=128 
Figure 8. Genetic testing recommendations following Genetics evaluation. Sixty 
percent of patients had genetic testing recommended following their Genetics 
consultation and 10%  of patients had genetic testing recommended if Cardiology or 
Ophthalmology examinations were abnormal or following the retrieval of familial 
genetic testing records (Genetic Testing TBD category). N=128  
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Figure 9. Types of genetic testing recommended. The most common type of genetic testing 
recommended was a large gene panel (52%). The large gene panels ranged in size from 4 genes 
to 61 genes. The most common large gene panel that was recommended was a 21-gene 
Aortopathy panel. See Appendix I for a list of the genes ordered and the gene panels.  
18%
1%
8%
4%
52%
8%
8% 1%
Single gene
Single gene with relex to other
genes
Two genes
Three genes
Larger gene panel
Microarray
WES
Recommended but not specified
N=85
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DISCUSSION 
I. Referral information 
This study aims to better understand which providers are referring patients to Genetics for 
EDS and other possible CTDs, what types of evaluations patients are having prior to seeing 
Genetics, and what types of recommendations Genetics is making after they assess these patients 
with the hopes that this information can provide guidance in evaluating these patients in the most 
effective and efficient way. There has been an increasing number of referrals to the Genetics 
specialty for an evaluation of EDS or to rule out another possible CTD. There were a total of 255 
referrals for this indication from January 2014 - May 2019 at UCIMC. Referrals for this 
indication at UCIMC have increased since the beginning of 2017, but the clinic capacity and the 
number of patients seen for this indication has remained the same (Table 1). Determination of the 
6%
68%
26%
Positive
Negative
VUS
N=37
Figure 10. Genetic testing outcomes. Thirty-seven patients had record of genetic testing. 
Three individuals (6%) had a positive genetic testing result.  
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exact reason for the increasing number of referrals is outside of the limits of this research project, 
but it was noted that attached to several patient referrals were referral denial letters from other 
Genetics clinics saying their practice no longer sees patients for the indications of EDS or 
possible CTD. This may explain why UCIMC has received an increase in referrals. It should also 
be noted that the International EDS Consortium proposed a new classification system of the 
thirteen different subtypes of EDS and outlined new diagnostic criteria for hEDS in an article 
published at the beginning of  2017 [Malfait et al., 2017]. Perhaps with this publication came 
more awareness for EDS and more inclination to refer these patients to Genetics because Criteria 
3 of the new hEDS diagnostic criteria states that other possible CTDs should be ruled out 
(Appendix D). In the two years since its publication, this article has been cited in 50 articles from 
a wide range of journals in the PubMed database. The article has been cited in Gastroenterology 
Research, the Journal of Clinical Sleep Medicine, Pediatric Rheumatology, Neurogenetics, 
Obstetric Medicine, and the Journal of Physical Therapy Science, just to name a few. It is 
evident that patients with EDS have a range of clinical features requiring multiple specialists, 
and that the syndrome is likely somewhat familiar to specialties other than Genetics.  
Because patients with EDS can have many different phenotypes requiring multiple care 
specialists, this study aimed to better understand which providers are referring patients to the 
Genetics specialty and to determine what types of evaluations (imaging or evaluations from other 
specialists) these patients are undergoing prior to seeing Genetics to determine if they have a 
possible CTD. By better understanding this information, Genetics can more effectively and 
efficiently manage the increasing load of patients referred for EDS or other possible CTD. 
Patients were referred to the Genetics specialty from 15 different types of providers. The most 
common referring providers were general practice providers (primary care, internal medicine, 
and family medicine physicians) or rheumatologists (Figure 1). This is unsurprising because a 
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study surveying 466 individuals with hEDS found that most individuals with hEDS were 
diagnosed in Genetics or Rheumatology clinics, and the majority of patients with hEDS reported 
that their primary care physician is the physician that manages their diagnosis [Murray et al., 
2013].   
The Beighton score is an important assessment for determining if a patient has GJH. An 
individual must meet the age-specific cutoff Beighton score to fulfill Criteria 1 for a diagnosis of 
hEDS (Appendix D). It is not a requirement that a provider referring a patient to Genetics give a 
Beighton score on their referral, but a referring provider might do their own assessment for EDS 
(including a Beighton score) before referring to Genetics. Of the 151 referrals that were 
analyzed, 33 referrals had a Beighton score documented. Twenty-five of these individuals were 
seen by Genetics and given a Beighton score by the medical geneticist, and of those, 19 were 
given a different Beighton score by their referring provider and the geneticist. For 6 of these 
individuals, the change in Beighton score given by the geneticist changed whether or not they 
met the age-specific cut-off for a diagnosis of GJH. Four individuals were given a lower 
Beighton score meaning they no longer met Criteria 1 for hEDS (Figure 2). This can be 
challenging emotionally for some patients who attributed their constellation of symptoms to a 
particular disorder like hEDS and then learned they did not meet diagnostic criteria for that 
diagnosis upon further evaluation. The Beighton score should be a standard measurement of 
hypermobility, however a provider’s judgment of giving points will inevitably vary. For this 
reason, it may not be necessary to have a referring provider give the patient a Beighton score, but 
if a Beighton score is provided along with other physical features it can help give the Genetics 
clinic an initial idea of what type of EDS the referring provider is suspicious of and this may help 
triage referrals.  
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This study found that non-hypermobility features of EDS, particularly skin features which 
are diagnostic criteria for various EDS subtypes, were much less frequently reported on referrals 
than on Genetics exams (Figure 3). More outreach and education regarding the updated criteria 
for EDS, especially hEDS, to the medical community may help other physicians assess patients 
for EDS and other possible CTDs and make appropriate referrals to Genetics with more clinical 
documentation specific to EDS.  
A unique aspect of an evaluation in the Genetics specialty is an evaluation or notation of 
features or problems across all systems in the body. For example, cardiologists may be focused 
solely on the heart and vascular system. General practice physicians may address all systems of 
the body when the need arises, but geneticists are trained in dysmorphology and to examine the 
full body to try to tie together features from different systems. Patients with different forms of 
EDS have features across different body systems (musculoskeletal, cardiac, eye findings, skin 
findings, etc.) so a Genetics evaluation may be useful to try to put all of the patients’ features 
together.  This is evident in the number of features discussed during the Genetics evaluation 
compared to the number of features noted in the referrals from other specialists. The average 
number of features listed in the Genetics consultation note was 7.1 features, while the average 
number of features given on the referral notes/documentation from other specialists or general 
practice physicians was 3.8 features (Table 4). This was statistically significant (p<0.001) 
meaning patients are discussing more symptoms or health conditions with Genetics providers 
and additional physical features are noted on the Genetics physical exam . It is important for a 
geneticist and genetic counselor to have a thorough medical history to guide them to differential 
diagnoses and determine what type of genetic testing may be indicated. However, with more 
features/problems that are discussed this will mean more time spent with these patients. 
Geneticists and genetic counselors spend a considerable amount of time (arguably more time 
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than other specialties) with patients and doing patient-related activates such as clinical 
documentation, literature review, reviewing records from outside providers, and writing family 
letters. McPherson et al. tracked the time medical geneticists and genetic counselors spent face-
to-face with patients and on patient-related activities and found that they spent an average of 7 
hours for each new patient and 3.5 hours on return patients [McPherson et al., 2008]. The 
increased amount of time needed is a concern when there is an increasing number of referrals to 
Genetics for this indication. 
 
II. Patients who were given a diagnosis of hEDS 
All of the patients who were given a diagnosis of hEDS had musculoskeletal findings, 8.8% 
reported vascular system findings, 35.3% reported cardiac findings, 55.9% reported 
gastrointestinal findings, 8.8% reported genitourinary findings, 61.8% reported having or had 
skin findings on physical examination, 32.4% reported immunologic findings, 2.9% reported 
endocrine findings, 55.9% reported neurological findings, 8.8% had structural brain 
abnormalities, 32.4% reported behavioral findings, and 17.6% had dental findings on physical 
examination. These reported features are consistent with other clinical studies and a patient 
survey of clinical manifestations associated with hEDS [Tinkle et al., 2017; Castori et al., 2010; 
Murray et al., 2013]. Patients with hEDS had an average of 8.5 clinical features noted during 
their Genetics consultation, while patients who were not given a diagnosis of hEDS had an 
average of 6.6 features noted during their Genetics consultation (p=0.003). As previously 
mentioned, discussing more medical concerns and obtaining record of more medical diagnoses, 
takes a considerable amount of time for geneticists and genetic counselors. It may be necessary 
to allot more time at the initial Genetics visit or arrange return visits for patients referred for this 
indication to discuss medical history and provide appropriate counseling. It would also be 
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beneficial for referring providers to send available medical records of clinic notes and imaging 
with the referrals to Genetics.  
Twenty-six patients who were given the diagnosis of hEDS were recommended to arrange a 
return visit to Genetics, most of whom were recommended to return to discuss genetic testing 
results. Seven patients with hEDS returned to clinic for at least one follow-up visit, which 
accounts for almost half (46.7%) of the total number patients in this study who returned for a 
follow-up visit. The exact reason for a low follow-up visit return rate is beyond the scope of this 
study, but perhaps some patients were given negative genetic testing results over the phone and 
no longer needed a follow-up visit or the patient received further care elsewhere. Genetics is 
often not the specialty that primarily manages hEDS patients’ care long term, but Genetics can 
provide education and facilitate a discussion surrounding improving the patients’ quality of life 
with both the patient and the physicians who will be managing the patient’s care. Genetics can 
discuss precautions or activities to avoid so patients do not exacerbate pain and fatigue 
symptoms [Greenen, R and Lumley, 2018] and they can also provide referrals to other specialists 
such as physical therapists in the community who know the limitations of individuals with hEDS 
or an HSD and other specialists who can treat and manage pain symptoms and musculoskeletal 
manifestations.  
 
III. Outcomes of recommendations made by Genetics 
When evaluating a patient for hEDS, other heritable or acquired CTDs should be ruled out to 
fulfill Criteria 3 for a diagnosis of hEDS. Patients are often referred to other specialists such as 
Cardiology and Ophthalmology to rule out features that may suggest another CTD. For example, 
an Ophthalmology finding of a lens dislocation is suggestive of Marfan syndrome. Geneticists 
and genetic counselors can, and often do, refer patients to these other specialists to help evaluate 
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for a possible CTD, but they do not always receive record of these evaluations being completed. 
UCIMC Genetics received Cardiology reports from 33.3% of the patients they referred, 
Ophthalmology reports from 28.6% of the patients they referred (Table 7), and echocardiogram 
reports from 42.4% of the patients they referred (Table 8). Of note, some echocardiogram reports 
received did not include the Z-score for assessing aortic root dilation. One explanation for this 
low rate of receiving reports may be that some of the patients referred to these specialists may 
not have completed visits, but if a patient is suspected of having EDS or another possible CTD it 
is an important part of their evaluation to be assessed for serious health risks such as aortic root 
dilation. It is possible that patients had these evaluations done, but Genetics did not receive 
record of the outcome. It can be challenging and time consuming to request and review records 
from outside medical facilities and clinics. One study evaluated the success rate and time it took 
for genetic counselors to request and receive records for family members suspected of having 
Alzheimer disease. Genetic counselors in this study received 33.5% of the familial records they 
requested and spent 500 hours during the 24 month study period trying to obtain the records 
[Alexander et al., 2011]. It is difficult and time consuming to request and receive patient records 
form other institutions and if patients should have a Cardiology evaluation and/or an 
echocardiogram or Ophthalmology evaluations to rule out other possible CTDs, it may be 
beneficial for patients to have these evaluations prior to seeing Genetics and not be scheduled 
with Genetics until the records are reviewed. Requiring patients to have an Ophthalmology exam 
or Cardiology evaluation and/or an echocardiogram prior to being scheduled in Genetics may 
become a barrier to some patients having an evaluation with Genetics due to insurance 
authorization or other limitations and it would still require the time of Genetics clinic 
administrators or schedulers to keep track of the records that are received prior to being 
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scheduled. The capacity of a Genetics clinic to recommend evaluations prior to being scheduled 
should be considered on an individual basis.  
Evaluations from Ophthalmology or findings from an echocardiogram may guide geneticists 
and genetic counselors to recommend genetic testing for particular CTDs.  Geneticists and 
genetic counselors may also recommend genetic testing without those evaluations if a patient has 
enough clinical features on exam to make them suspicious of a CTD, or they may recommend 
testing to try to rule out the possibility of one of the life-threatening CTDs such as vEDS. In this 
study, 60% of the 128 patients seen by Genetics had genetic testing recommended following 
their evaluation and 10% of patients had genetic testing recommended if 
Cardiology/echocardiogram or Ophthalmology examinations were abnormal or following the 
retrieval of familial genetic testing records (Figure 8). The majority of patients’ genetic testing 
results were negative (68%), but 3 (6%) patients had positive results (Figure 10). One patient 
(#300) was found to have a variant in the CACNA1S gene on WES. This variant described the 
patient’s phenotype of hemiplegic migraines well but did not explain the hEDS features for 
which he was referred. Another patient (#59) was initially referred to Genetics for suspicion of 
Marfan syndrome and intellectual disability with a previously abnormal karyotype. A 
chromosome microarray was ordered by Genetics and the patient was found to have 9q34 
duplication syndrome, which described both his intellectual disability and Marfanoid habitus 
well. The accurate diagnosis of a genetic condition can help guide clinical management and 
prognosis. In the case of patient #59, individuals with 9q34 duplication syndrome have the 
musculoskeletal features of Marfan syndrome, but lack the serious cardiovascular and ocular 
system manifestations, so they do not require the same screening as individuals with Marfan. The 
third patient (#36) had a diagnosis of vEDS confirmed when a pathogenic variant in COL3A1 
was found, which has great implications for his health management and possibly other family 
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members. More often than not, genetic testing yields negative results, but even negative results 
can provide information and lower the suspicion of particular genetic disorders that can have 
serious implications for a patient’s health and management. Geneticists and genetic counselors 
can still treat or provide recommendations for patients’ symptoms in the absence of a confirmed 
genetic condition. Genetic counselors are also trained to provide medical, educational, financial 
and psychosocial resources [Accreditation Council for Genetic Counseling, 2015], which can be 
of great value to patients.  
 
IV. Self-referred patients  
It is clear that patients who are referred to Genetics for EDS or other possible CTDs have 
many clinical features and concerns. Having documentation of their clinical features and 
previous evaluations prior to being seen by Genetics is helpful to be able to give a 
comprehensive Genetic evaluation. A concern of accepting self-referred patients is that there will 
be a lack of clinical information initially or that these patients will be less likely to have seen 
other specialists and will therefore require Genetics to make more recommendations and 
coordinate more follow-up. The number of patients who had imaging or evaluations by different 
specialists (Cardiology, Ophthalmology, Rheumatology, Orthopedics, and Immunology/Allergy) 
prior to seeing Genetics were compared between self-referred patients and provider-referred 
patients. The recommendations of imaging studies, requests to review outside medical records, 
referrals to other specialists and return visits made following the Genetics consultation were also 
counted and compared between the two groups. Whether or not someone was self-referred to 
Genetics did not determine how frequently or infrequently they saw other specialists or had 
imaging done prior to seeing Genetics (Table 3). There was also no statistically significant 
difference in the number of recommendations made following the Genetics consultation between 
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self-referred and provider-referred patients (Table 6). It is possible that this study did not have 
sufficient power to identify a small difference if one was there, or perhaps this may be unique to 
patients with EDS. One study found that 21 patients with hEDS saw 20 different providers 
before obtaining their diagnosis [Castori et al., 2010] and due to the number and severity of 
symptoms these patients have, they may be more self-motivated to seek care from different 
specialties. Based on the data from this study, it is not necessary to deny a patient for an 
evaluation of EDS if they are self-referred for lack of prior evaluations or worry of extra follow-
up required for these patients. Nevertheless, it is important that self-referred patients have an 
established care provider if Genetics is not going to be the main provider that manages their care.  
 
V. Conclusion 
There is value in a Genetics evaluation for EDS and possible CTDs. Geneticists perform a 
full body exam and assess a patient’s features across all systems of the body which is important 
for individuals with EDS and other CTDs who have clinical manifestations across many body 
systems. Genetic counselors are trained to provide medical, educational, financial and 
psychosocial resources for their patients [Accreditation Council for Genetic Counseling, 2015], 
so even if genetic testing is not indicated, the Genetics clinic offers education and support to 
patients with suspected EDS and the providers who manage their care. The number of referrals 
for EDS and CTDs is increasing at UCIMC and the load of referrals can be difficult to keep up 
with. This may be an opportunity to educate referring providers about the new EDS 
classifications and diagnostic criteria published by Malfait et al. [2017] and the utility of other 
evaluations such as an Ophthalmology exam and an echocardiogram prior to seeing Genetics so 
the patient can get the most out of a Genetics consultation. This study was limited by reviewing 
charts at a single Genetics clinic site with only five different geneticists performing clinical 
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evaluations throughout the study period. This study focused on the Genetics clinic perspective of 
evaluations for EDS and CTDs, but future studies could survey patients to try to further 
understand their goals for a Genetics evaluation. With a better understanding of the challenges of 
evaluating patients for EDS and the goals of this patient population, Genetics can provide a 
comprehensive evaluation for EDS and provide the support these patients need.  
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APPENDIX A 
Classification of the Ehlers-Danlos syndrome subtypes, inheritance pattern (IP), and 
genetic basis adapted from Malfait, et al., 2017 
Clinical EDS 
Subtype Abbreviation IP Genetic Basis Protein 
Classical EDS cEDS AD 
Major: COL5A1, 
COL5A2  
Type V 
collagen 
Rare: COL1A1 
c.934C>T, 
p.Arg312Cys 
Type I collagen 
Classical-like EDS clEDS AR TNXB Tenascin XB 
Cardiac-valvular 
EDS cvEDS AR COL1A2 Type I collagen 
Vascular EDS vEDS AD 
Major: COL5A1 Type III collagen 
Rare: COL1A1 Type I collagen 
c.934C>T, 
p.Arg312Cys  
c.1720C>T, 
p.Arg574Cys  
c.3227C>T, 
p.Arg1093Cys  
Hypermobile EDS hEDS AD Unknown Unknown 
Arthrochalasia EDS aEDS AD COL1A1, COL1A2 Type I collagen 
Dermatosparaxis 
EDS dEDS AR ADAMTS2 ADAMTS-2 
Kyphoscoliotic EDS kEDS AR 
PLOD1 LH1 
FKBP14 FKBP22 
Brittle Cornea 
syndrome BCS AR 
ZNF469 ZNF469 
PRDM5 PRDM5 
Spondylodysplastic 
EDS spEDS AR 
B4GALT7 β4GalT7 
B3GALT6 β3GalT6 
SLC39A13 ZIP13 
Musculocontractural 
EDS mcEDS AR 
CHST14 D4ST1 
DSE DSE 
Myopathic EDS mEDS AD or AR COL12A1 
Type XII 
collagen 
Periodontal EDS pEDS AD 
C1R C1r 
C1S C1s 
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APPENDIX B 
 
Criteria for Classical EDS (cEDS) diagnosis as outlined by Malfait, et al. 2017 
Major Minor 
1. Skin hyperextensibility and 
atrophic scarring 
1. Easy bruising 
2. Generalized joint hypermobility 
(GJH) 
2. Soft, doughy skin 
  3. Skin fragility (or traumatic splitting) 
  4. Molluscoid pseudotumors 
  5. Subcutaneous spheroids 
  6. Hernia (or history thereof) 
  7. Epicanthal folds 
  8. Complications of joint hypermobility 
(sprains, luxations/subluxation, pain, 
flexible flatfoot) 
  9. Family history of first degree relative who 
meets clinical criteria 
Minimal criteria for cEDS is major criteria 1 (skin hyperextensibility and atrophic 
scarring) PLUS either major criteria 2 (GJH) and/or three minor criteria. 
Confirmatory molecular testing is obligatory to diagnose. 
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APPENDIX C 
 
Criteria for Vascular EDS (vEDS) diagnosis as outlined by Malfait, F. et al. 2017 
Major Minor 
1. Family history of vEDS with 
documented causative variant in 
COL3A1 
1. Bruising unrelated to identified trauma 
and/or in unusual sites such as cheeks and 
back 
2. Arterial rupture at a young age 2. Thin, translucent skin with increased 
venous visibility 
3. Spontaneous sigmoid colon 
perforation in the absence of a known 
diverticular disease or other bowel 
pathology 
3. Characteristic facial appearance 
4. Spontaneous pneumothorax 
5. Acrogeria 
6. Talipes equinovarus 
4. Uterine rupture during the third 
trimester in the absence of previous C-
section and/or severe peripartum 
perineum tears 
7. Congenital hip dislocation 
8. Hypermobility of the small joints 
9. Tendon or muscle rupture 
10. Keratoconus 
11. Gingival recession and gingival fragility 
5. Carotid-cavernous sinus fistula 
(CCSF) formation in the absence of 
trauma 
12. Early onset varicose veins (under age 30 
and nulliparous if female) 
Minimal criteria suggestive of diagnostic studies for vEDS includes: a family history 
of vEDS, arterial rupture or dissection in individuals less than 40 years of age, 
unexplained sigmoid colon rupture, or spontaneous pneumothorax in the presence of 
other features consistent with vEDS. Testing for vEDS should also be considered in 
the presence of a combination of other "minor" features. Confirmatory molecular 
testing is obligatory to diagnose.  
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APPENDIX D 
Criteria for a clinical diagnosis of hypermobility EDS (hEDS) as outlined by Malfait, et al., 2017 
Criteria 1- Generalized Joint 
Hypermobility 
Criteria 2- two or more of the following 
features (A, B, C) must be present 
Criteria 3- All of the following 
prerequisites MUST be met 
Beighton Score consistent with GJH based 
on age: 
Feature A (five must be present) 
(Musculoskeletal features) 
1. Absence of unusual skin fragility, which 
should prompt consideration of other types 
of EDS 
≥6 pre-pubertal children and adolescents 1. Unusually soft or velvety skin 
≥5 pubertal men and women to age 50 2. Mild skin hyperextensibility 2. Exclusion of other heritable and acquired 
connective tissue disorders (CTD), including 
autoimmune rheumatologic conditions. In 
patients with acquired CTD (e.g. arthritis), 
additional diagnosis of hEDS requires 
meeting Features A and B or Criteria 2 and 
Feature C of Criteria 2 cannot be counted 
toward diagnosis of hEDS  
≥4 men and women over age 50 3. Unexplained striae distensae or rubae at the 
back, groins, thighs, breasts and/or abdomen 
in adolescents, men or pre-pubertal women 
without a significant history of significant 
gain or loss of weight 
If Beighton Score is one point below age 
cut-off, two or more of the following must 
also be present to meet criteria: 
4. Bilateral piezogenic papules of the heel 3. Exclusion of alternative diagnoses that 
may also include joint hypermobility by 
means of hypotonia and/or connective tissue 
laxity. Alternative diagnoses and diagnostic 
categories include, but are not limited to: 
neuromuscular disorders, other hereditary 
CTDs, and skeletal dysplasias. Exclusion of 
these considerations may be based on 
history, physical exam, and/or molecular 
genetic testing as indicated 
5. Recurrent or multiple abdominal hernia(s) 
1.Can you now (or could you ever) place 
your hands flat on the floor without bending 
your knees? 
6. Atrophos scarring involving at least two 
sites and without the formation of truly 
papyraceous and/or hemosideric scars as seen 
in cEDS 
2.Can you now (or could you ever) bend 
your thumb to touch your forearm? 
7. Pelvic floor, rectal, and/or uterine prolapse 
in children, men or nulliparous women 
without a history of morbid obesity or other 
known predisposing medical condition 3.As a child, did you amuse your friends by 
contorting your body into strange shapes or 
could you do the splits? 
 
4.As a child or teenager, did your shoulder 
or kneecap dislocate on more than one 
occasion? 
8. Dental crowding and high or narrow palate 
 
5.Do you consider yourself "double 
jointed"? 
9. Arachnodactyly as defined by one or more 
of the following: i) positive wrist sign on both 
sides, or ii) positive thumb sign on both sides 
 
 
10. Arm span-to-height ratio ≥1.05 
 
11. Mitral valve prolapse mild or greater 
based on echocardiogram criteria 
 
 
12. Aortic root dilation with Z-score >+2 
 
 
Feature B 
 
 
Positive family history (one or more first 
degree relative independently meeting the 
current criteria for hEDS) 
 
 
Feature C- Must have at least one 
 
 
1. Musculoskeletal pain in two or more limbs, 
recurring daily for at least 3 months 
 
 
2. Chronic, widespread pain for ≥ 3 months 
 
 
3. Recurrent joint dislocations or frank joint 
instability, in the absence of trauma 
 
Criteria 1, 2, and 3 must ALL be met for a clinical diagnosis of hEDS 
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APPENDIX E 
 
Hypermobility Spectrum Disorders (adapted from Castori, et al. 2017) 
HSD Classification Beighton Score Musculoskeletal Involvement 
Asymptomatic GJH  Positive Absent 
Asymptomatic PJH  Usually Negative Absent 
Asymptomatic LJH  Negative Absent 
Generalized hypermobility spectrum 
disorder G-HSD Positive Present 
Peripheral hypermobility spectrum 
disorder P-HSD Usually Negative Present 
Localized hypermobility spectrum 
disorder L-HSD Negative Present 
Historical hypermobility spectrum 
disorder  H-HSD Negative Present 
 
  
 57 
APPENDIX F 
Clinical features listed on referrals or Genetics consultation note in each phenotypic 
category 
 
Noted on Referral 
(N=151) 
Noted on Genetics 
Consultation Note 
(N=128) 
Musculoskeletal Findings   
arachnodactyly 1 17 
arm span: height ratio >1.05 1 2 
arthritis 12 16 
atrophy of muscle 1 0 
chronic cervical radiculopathy 0 1 
degenerative disk disease 2 1 
dislocations/subluxations  35 59 
dural ectasia 1 1 
easy bruising 13 45 
“EDS” or “EDS symptoms” 7 0 
facial features 0 4 
fatigue 29 26 
fibromyalgia 12 13 
fractures/ stress fractures 3 1 
Gorlin sign 0 2 
gout 0 1 
joint hypermobility 82 87 
joints “lock” 0 2 
kyphosis 0 2 
muscle cramps 0 1 
osteoporosis 1 0 
pain (joint, musculoskeletal, chronic) 69 83 
patellar instability 0 1 
pectus deformity 0 9 
pes planus 2 9 
possible fibromuscular dysplasia  1 1 
protrosio acetabula 0 1 
rectal/uterine/pelvic floor prolapse  6 6 
scoliosis 6 22 
small fiber neuropathy 0 1 
spondylolisthesis 0 1 
“suspicion of Marfan” 19 0 
talipes equinovarus 1 3 
 58 
temporomandibular joint dysfunction 6 15 
tendon rupture 0 1 
tendon tear 1 5 
tissue fragility during surgery 1 1 
uterine rupture 1 1 
Vascular Findings   
abnormal angiography 1 0 
aortic aneurysm 4 3 
artery dissection 7 7 
excessive bleeding 4 4 
stroke 4 5 
varicose veins 1 5 
venous insufficiency 0 2 
Cardiac Findings   
aberrant right subclavian artery 1 0 
aortic root dilation 4 4 
arrhythmia 0 2 
atrial fibrillation 0 1 
mitral valve prolapse  3 7 
pericardial effusion 1 0 
POTS 13 19 
positional hypotension 2 2 
tachycardia 4 3 
thoracic outlet syndrome 1 2 
tricuspid regurgitation 4 6 
Gastrointestinal Findings   
abdominal pain 7 9 
bowel obstruction 0 1 
cecal volvus 1 1 
colon perforation 1 0 
delayed gastric emptying 1 0 
esophagitis 0 2 
GI disturbance 
(constipation/diarrhea/irritable bowel 
syndrome/disease) 20 46 
intussusception 1 0 
rectal duplication cysts 1 1 
Genitourinary/ Gynecological Findings   
abdominal hernia 4 1 
endometriosis 1 2 
 59 
hiatal hernia 2 6 
inguinal hernia 3 4 
interstitial cystitis 0 2 
overactive bladder 1 0 
Skin Findings   
Acrogeria 0 1 
atrophic/abnormal/wide scarring 2 21 
easy tearing of the skin 0 5 
heel papules 0 6 
poor wound healing 2 6 
skin elasticity 0 14 
“skin findings” 1 0 
skin striae 4 25 
thin/translucent skin 2 6 
velvety/soft skin 0 24 
Eye Defects/Vision   
blue sclera 0 1 
“cracks on retina” 0 1 
dry eyes 0 1 
eye pain 3 1 
macular degeneration 0 1 
myopia 2 18 
retinal detachment 1 2 
Hematologic/Immunologic Findings   
Anemia 1 0 
autoimmune disorder/frequent illness or 
infection 4 10 
Lyme disease 0 1 
mast cell activation disorder 7 8 
mastocytosis 1 2 
Sjögrens disease 1 0 
Endocrine Findings   
Cushing’s disease 1 1 
panhypopituitarism 1 1 
Hearing Impairment   
hearing loss 3 2 
Neurological Findings   
abnormal gait 1 0 
ataxia 0 1 
auditory processing disorder 0 1 
 60 
brain fog 5 8 
dysautonomia 5 7 
dysphasia 1 1 
expressive aphasia 0 1 
hemiplegic migraine 1 1 
lightheaded 2 0 
migraines/headaches 30 43 
“memory problems” 1 0 
multiple sclerosis 0 1 
poor balance 1 0 
syncope 4 0 
tremors 2 4 
vertigo 0 1 
Structural Brain/Spine Abnormalities   
Arnold Chiari malformation 7 9 
carotid cavernous fistula 1 1 
tarlov cysts of the spine 1 1 
Behavioral/Developmental Findings   
anxiety/ depression 33 27 
insomnia/poor sleep 11 12 
intellectual disability 0 1 
Respiratory Findings   
pneumothorax 4 6 
Dental Findings   
bifid uvula 0 2 
dental crowding/ high or narrow palate 2 21 
gingival recession 0 1 
poor/worsening dentition 1 0 
Metabolic Findings   
low alkaline phosphatase 1 1 
elevated homocysteine 1 0 
hyperprolactinemia 1 0 
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APPENDIX G 
 
Clinical features listed on referrals and Genetics consultation notes 
Feature 
Referrals Genetics Consultation 
N=151 N=128 
N(%) N(%) 
Musculoskeletal Findings 129 (85.4) 125 (97.7) 
Vascular System 18 (11.9) 21 (16.4) 
Cardiac Findings 33 (21.9) 38 (29.7) 
Gastrointestinal Findings 24 (15.9) 51 (39.8) 
Genitourinary/Gynecological Findings 10 (6.6) 14 (10.9) 
Skin Findings 11 (7.3) 67 (52.3) 
Eye Defects/Vision 8 (5.3) 24 (18.8) 
Hematologic or Immunologic Findings 11 (7.3) 20 (15.6) 
Endocrine Findings 1 (0.7) 1 (0.8) 
Hearing Impairment 3 (2.0) 2 (1.6) 
Neurological Findings 45 (29.8) 55 (43.0) 
Structural Brain/Spine Abnormalities 9 (6.0) 11 (8.6) 
Behavioral/Developmental Findings 38 (25.2) 35 (27.3) 
Respiratory Findings 4 (2.6) 6 (4.7) 
Dental Findings 3 (2.0) 23 (18.0) 
Metabolic Findings 3 (2.0) 1 (0.8) 
 
  
 62 
APPENDIX H 
 
Number of referrals placed to other specialties following 
Genetics evaluation 
 N=128 
Specialists N (%) 
Cardiology 21 (16.4) 
Ophthalmology 28 (21.9) 
Rheumatology 2 (1.6) 
Pain Management 7 (5.5) 
Physical Therapy 7 (5.5) 
Neurology 4 (3.1) 
Orthopedics 3 (2.3) 
Immunology/Allergy 6 (4.7) 
Local EDS specialist 6 (4.7) 
Gastroenterology 3 (2.3) 
Cancer Genetic Counseling 3 (2.3) 
Dermatology 1 (0.8) 
Otolaryngology 1 (0.8) 
Social Work 1 (0.8) 
Mental Health specialist 1 (0.8) 
Nephrology 1 (0.8) 
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APPENDIX I 
 
Types of genetic testing recommended/ordered 
 
Single genes 
COL3A1 
FBN1 
GLA 
IKBKAP1 
KIT 
PLOD1 
site specific CYP2D6  
site specific familial variant 
TNXB 
 
Two genes 
COL5A1, COL5A2 
FBN1, FLCN 
TGFB1, TGFB2 
 
Three genes 
COL3A1, COL5A1, COL5A2 
 
Larger gene panels 
5 gene “EDS Panel” COL1A1, COL1A2, COL3A1, COL5A1, COL5A2 
10 gene “Vascular Panel” ACTA2, COL3A1, FBN1, MYH11, MYLK, PRKG1, SMAD3,TGFB2, 
 TGFBR1, TGFBR2  
14 gene “Marfan Syndrome and Related Aortopathies Panel” ACTA2, COL3A1, COL5A1, 
 COL5A2, FBN1, FBN2, MYH11, MYLK, SKI, SLC2A10, SMAD3, TGFB2, TGFBR1, 
 TGFBR2 
15 gene “TAADNext” ACTA2, CBS, COL3A1, COL5A1, COL5A2, FBN1, FBN2, FLNA, 
 MED12, MYH11, SKI, SLC2A10, SMAD3, TGFBR1, TGFBR2 
18 gene “EDS Panel” ADAMTS2, ATP7A, B3GALT6, B3GALT7, CHST14, CHST3, COL1A1, 
 COL1A2, COL3A1, COL5A1, COL5A2, FKBP14, FLNA, FLNB, PLOD1, SLC39A13, 
 ZNF469 
21 gene “Aortopathy Panel” ACTA2, CBS, COL3A1, COL5A1, COL5A2, EFEMP2, FBN1, 
 FBN2, FLNA,  MYH11, MYLK, PLOD1, PLOD3, PRKG1, SKI , SLC2A10, SMAD3, 
 SMAD4, TGFB2, TGFBR1, TGFBR2 
37 gene “Connective Tissue NGS Panel” ABCC6, ACTA2, ACVR1, ADAMTS2, CBS, CHST14, 
  COL11A1, COL1A1, COL2A1, COL3A1, COL4A1, COL5A1, COL5A2, ELN, FBLN5, 
 FBN1, FBN2, FKBP14, FLNA,  MED12, MYH11, MYLK, NOTCH1, PKD2, PLOD1, 
 PRDM5, SKI, SLC2A10, SLC39A13, SMAD3, SMAD4, TGFB2, TGFBR1, TGFBR2, 
 ZNF469 
4 gene “Neurofibromatosis Panel” NF1, NF2, SMARCB1, SPRED1 
61 gene “Bleeding Disorders Panel” 
152 gene “Otoscope Panel” 
 
